

## **Conflicts of Interest Document**

### **For:**

Urothelial bladder cancer extending to rectal mucosa via the prostate and mimicking hemorrhoidal bleeding with daily bright red blood per rectum coating stools: Novel case report and novel colonoscopic findings

### **By:**

Andrew M. Aneese M.D., M.S.<sup>1</sup>, Vinayata Manuballa D.O.<sup>2</sup>, Mitul Amin, M.D.<sup>3</sup>, and Mitchell S. Cappell, M.D., Ph.D.<sup>4</sup> (*Drs. Aneese and Cappell are equal, primary authors*)

Gastroenterology Resident<sup>1</sup>, Gastroenterology Fellow<sup>2</sup>, and Chief<sup>4</sup>, Division of Gastroenterology and Hepatology, Department of Medicine, William Beaumont Hospital, Royal Oak, MI, USA; Chairman, Department of Pathology<sup>3</sup>, William Beaumont Hospital, Royal Oak, MI, USA; and Professor of Anatomy<sup>3</sup>, and Professor of Medicine<sup>4</sup>, Oakland University William Beaumont School of Medicine, Royal Oak, MI, USA

**Conflicts of interest:** None. In particular, Dr. Cappell, as a consultant of the United States Food and Drug Administration (FDA) Advisory Committee for Gastrointestinal Drugs, affirms that this paper does not discuss any proprietary, confidential, pharmaceutical data submitted to the FDA. Dr. Cappell is also a member of the speaker's bureau for AstraZeneca and Daiichi Sankyo, co-marketers of Movantik. This work does not discuss any drug manufactured or marketed by AstraZeneca or Daiichi Sankyo.